Various extrarenal localizations of SGLT1 represent possible health risk in case of using novel inhibitors for diabetes treatment in humans, which are primarily aimed to inhibit the SGLT1-mediated reabsorption of glucose in kidneys ([31, 60] and references in there). This evidence concerns the gene SLC5A1 and diabetes mellitus.